Amenorrhea rates in women treated with novel oral, continuous hormonal therapy of body identical 17β-estradiol and micronized progesterone

Abstract

Introduction: Bleeding and spotting is a major reason of discontinuation of hormonal therapy (HT) among postmenopausal women (PW) who expect amenorrhea during that period of their lifetime. New oral combination therapy of 1 mg 17β-estradiol and 100 mg micronized progesterone (1 mg E2/100 mg P4) in a single softgel capsule is the first HT of naturally occurring E2 and P4 identical to human endogenous ovarian hormones (body-identical). It is approved in the US, Canada, and several EU countries; indicated in EU for the treatment of estrogen deficiency symptoms in PW with an intact uterus.